Ownership and insider activity for BioCryst Pharmaceuticals, Inc. (BCRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema.
Price
| Price | $8.43 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.1M | $50.3M | $26.7M | $114.2M | $272.1M | $504.4M | $304.8M | $110.6M | $104.9M | $89.7M |
| Short-term Investments | $32.5M | $64.1M | $77.7M | $22.1M | $28.2M | $3.2M | $119.5M | $278.3M | $216.1M | $185.0M |
| Receivables | $8.8M | $6.1M | $4.3M | $22.1M | $8.6M | $29.4M | $50.6M | $57.0M | $79.1M | $106.8M |
| Inventory | $500000 | -$37.8M | $1.6M | 0 | $7.0M | $15.8M | $27.5M | $28.7M | $8.1M | $5.4M |
| Total Current Assets | $67.0M | $125.4M | $114.4M | $164.3M | $323.8M | $566.1M | $516.5M | $496.0M | $422.0M | $404.3M |
| Property, Plant & Equipment | $9.9M | $9.5M | $9.1M | $7.3M | $7.1M | $15.2M | $8.6M | $20.9M | $19.8M | $19.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $89.8M | $178.3M | $146.8M | $175.3M | $334.7M | $588.2M | $550.0M | $517.0M | $490.4M | $514.2M |
| Accounts Payable | $4.3M | $6.3M | $7.8M | $14.0M | $18.7M | $27.8M | $14.4M | $20.9M | $11.6M | $15.8M |
| Short-term Debt | $28.2M | $35.1M | $33.7M | $38.6M | $30.0M | 0 | 0 | 0 | $35.4M | 0 |
| Total Current Liabilities | $54.4M | $74.8M | $69.5M | $92.3M | $105.7M | $103.7M | $105.5M | $150.0M | $160.4M | $196.1M |
| Long-term Debt | $22.8M | $16.8M | $25.4M | $41.3M | $244.5M | $585.5M | $733.3M | $811.3M | $795.9M | $427.2M |
| Total Liabilities | $88.3M | $94.5M | $97.6M | $137.0M | $354.0M | $695.1M | $844.6M | $972.5M | $966.4M | $633.3M |
| Retained Earnings | -$566.1M | -$631.8M | -$732.0M | -$840.6M | -$1.02B | -$1.21B | -$1.45B | -$1.68B | -$1.77B | -$1.51B |
| Total Equity | -$566.1M | -$631.8M | -$732.0M | $38.3M | -$19.3M | -$107.0M | -$294.6M | -$455.5M | -$475.9M | -$119.2M |
| Total Debt | $53.7M | $54.7M | $61.8M | $84.7M | $279.5M | $593.2M | $741.5M | $825.1M | $841.4M | $438.9M |
| Net Debt | -$9.9M | -$101.0M | -$65.0M | -$51.6M | -$20.9M | $85.6M | $317.1M | $436.2M | $520.4M | $164.1M |
| Working Capital | $12.6M | $50.6M | $44.9M | $72.0M | $218.1M | $462.4M | $411.0M | $346.0M | $261.6M | $208.3M |
Financial Health
| Debt / Equity | -0.90 |
| Current Ratio | 2.32 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.83 |
Profitability
| Return on Equity | 101.55% |
| Return on Invested Capital | -88.96% |
| Return on Assets | -68.96% |
| Gross Margin | 23.52% |
| Operating Margin | -33.29% |
| Net Margin | -40.90% |
Related companies: ARDX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explore sector: Healthcare · Biotechnology
More sections of BCRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks